Aprogen, Inc
Aprogen operates pharmaceutical and biopharmaceutical divisions producing synthetic drugs and antibody biosimilars alongside metal and insulation businesses.
As of 2026-10-10, Aprogen, Inc has 10 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1971, Aprogen listed on the KOSPI in 1995 as a diversified company spanning metals, pharmaceuticals, insulation, and biopharmaceuticals. Its pharmaceutical division (50.35% of sales) sells synthetic drugs such as the circulatory drug Rozettam Tablet and the digestive drug Easylong Oral Solution along with cosmetics, while its biopharmaceutical division develops four antibody biosimilars—for Herceptin, Humira, Rituxan, and Remicade—and a dual-receptor new drug for degenerative arthritis. It also runs Korea's No.1 metal hardfacing business (28.59% of sales) and the NUKON insulation system for nuclear power plants (2.05% of sales), posting total sales of KRW 117,974 million in its 55th fiscal year.
Products & technology
- 로젯탐정
- 엑사디핀정
- 글리콜린연질캡슐
- 토프라맥정
- 이지롱내복액
- 레바미피드정
- 가베스판연질캡슐
- 리버킹연질캡슐
- 네오히알주
- 히알로지 피이펙트 리라이언스 젤
- 허셉틴 바이오시밀러
- 휴미라 바이오시밀러
- 리툭산 바이오시밀러
- 레미케이드 바이오시밀러
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2026 (Phase 1 1)
- Phase 1AP2092026-06-09
4 trial sites
R&D and key agreements
Source: DART corporate disclosure퇴행성 관절염 치료용 이중 수용체 신약 · 퇴행성 관절염 · 연구개발 · Biopharmaceutical pipeline candidate (source text truncated after this point)
Key disclosures
KRX KIND via OpenDARTShow 42 more events
Publications
PubMed · affiliation-matched- The amoebicidal effect of Torreya nucifera extract on Acanthamoeba lugdunensis.
PloS one · 2023-01 · Kang MS, Kim S, Kim DS 외 2
- Mealworm Oil (MWO) Enhances Wound Healing Potential through the Activation of Fibroblast and Endothelial Cells.
Molecules (Basel, Switzerland) · 2021-02 · Kim JH, Kim EY, Chung KJ 외 4
- ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancer.
American journal of cancer research · 2021-01 · Jeong D, Ham J, Kim HW 외 12
- Pdlim4 is essential for CCR7-JNK-mediated dendritic cell migration and F-actin-related dendrite formation.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019-10 · Yoo JY, Jung NC, Lee JH 외 13
- Combined omics analysis identifies transmembrane 4 L6 family member 1 as a surface protein marker specific to human mesenchymal stem cells.
Stem cells and development · 2011-02 · Bae S, Shim SH, Park CW 외 5
- Substitution of glutamine by glutamate enhances production and galactosylation of recombinant IgG in Chinese hamster ovary cells.
Applied microbiology and biotechnology · 2010-10 · Hong JK, Cho SM, Yoon SK
- Monoclonal anti-thrombopoietin antibodies generated by genetic immunization.
Hybridoma (2005) · 2006-04 · Lim NK, Kim JH, Kim SY 외 5
- Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody.
The Journal of biological chemistry · 2006-03 · Yoon SO, Lee TS, Kim SJ 외 11
- An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.
Infection and immunity · 2005-10 · Lim NK, Kim JH, Oh MS 외 6
- A new epitope tag from hepatitis B virus preS1 for immunodetection, localization and affinity purification of recombinant proteins.
Journal of immunological methods · 2003-12 · Oh MS, Kim KS, Jang YK 외 6
Patents
KIPRIS · applicant-matchedPublished · 2024-05 · Application 1020240063212
Published · 2023-12 · Application 1020230191803
Withdrawn · 2022-09 · Application 1020247011765
US · Published · 2022-09 · Application 18691121
EP · Published · 2022-09 · Application 22870316.1
PCT · Published · 2022-09 · Application PCT/KR2022/013800
Rejected · 2022-01 · Application 1020220011973
US · Registered · 2021-09 · Application 17489885
Registered · 2021-06 · Application 1020210077576
Registered · 2019-11 · Application 1020190151817
Show 36 more patents
Registered · 2019-11 · Application 1020190148718
Registered · 2018-12 · Application 1020180169995
Registered · 2017-11 · Application 1020170151802
Registered · 2016-11 · Application 1020160147523
Registered · 2016-10 · Application 1020187011372
Registered · 2015-05 · Application 1020150070775
US · Published · 2013-03 · Application 13848015
Expired · 2012-12 · Application 1020147019693
PCT · Published · 2012-12 · Application PCT/KR2012/010929
US · Published · 2012-11 · Application 13653481
PCT · Published · 2010-10 · Application PCT/KR2010/007396
Expired · 2009-11 · Application 1020090109863
CN · Published · 2009-07 · Application 200980126484
EP · Registered · 2009-07 · Application 09794633.9
PCT · Published · 2009-07 · Application PCT/KR2009/003714
PCT · Published · 2008-12 · Application PCT/KR2008/007328
Expired · 2008-07 · Application 1020080066771
Registered · 2008-06 · Application 1020080058405
CN · Published · 2008-02 · Application 201810332855.2
Registered · 2008-02 · Application 1020097020284
EP · Registered · 2008-02 · Application 08788817.8
Expired · 2008-01 · Application 1020080002023
Expired · 2007-09 · Application 1020070094759
Expired · 2006-07 · Application 1020087004043
PCT · Published · 2006-03 · Application PCT/KR2006/000878
Withdrawn · 2006-01 · Application 1020060002862
Expired · 2005-09 · Application 1020077009529
EP · Registered · 2005-09 · Application 11008503.2
Withdrawn · 2005-07 · Application 1020050066875
Rejected · 2004-06 · Application 1020040041202
Expired · 2003-04 · Application 1020030024372
Expired · 2003-03 · Application 1020047014513
EP · Registered · 2003-03 · Application 03745028.5
PCT · Published · 2003-03 · Application PCT/KR2003/000564
Expired · 2001-09 · Application 1020010060770
Rejected · 1995-04 · Application 1019950010680
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot56
- AnthropicClaudeBot2
- GoogleGoogleOther1
- PerplexityPerplexityBot1
Measured since Aug 27, 2026 · 4 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Aprogen, Inc and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryPharma & CDMO
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition